In the BioHarmony Drug Report Database
Alfuzosin
Uroxatral (alfuzosin) is a small molecule pharmaceutical. Alfuzosin was first approved as Uroxatral on 2003-06-12. It is used to treat prostatic hyperplasia in the USA. The pharmaceutical is active against alpha-1B adrenergic receptor, alpha-1D adrenergic receptor, and alpha-1A adrenergic receptor.
Trade Name
|
Uroxatral |
|---|---|
Common Name
|
alfuzosin |
ChEMBL ID
|
CHEMBL709 |
Indication
|
prostatic hyperplasia |
Drug Class
|
Image (chem structure or protein)